Clinical Trial Update: Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy

View source ↗

Summary

A completed AstraZeneca trial evaluated whether concomitant proton pump inhibitor use influences the risk of discontinuing low-dose aspirin during the first yea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• Aspirin (Aspirin)

Snippet

Sponsor: AstraZeneca | Conditions: Cardiovascular Prevention | Status: COMPLETED